Roivant Sciences Ltd. reported a net loss attributable to the company of $113.5 million for the three months ended September 30, 2025, compared to a net loss of $230.2 million for the same period in 2024. Basic and diluted net loss per common share was $0.17, down from $0.31 in the prior year period. As of September 30, 2025, Roivant had $1.2 billion in cash, cash equivalents, and restricted cash, and $3.1 billion in marketable securities, supporting a cash runway into profitability. Total assets stood at $5.1 billion, with total liabilities of $257.1 million and total shareholders' equity of $4.8 billion. Recent business developments included positive brepocitinib data in dermatomyositis and Immunovant's remission data in Graves' disease. Roivant announced plans to provide further updates during its investor day in December 2025.